Role of CD44 in tumour progression and strategies for targeting

References

• Abney JR, Braun J, Owicki JC. (1987). Lateral interactions among membrane proteins. Implications for the organization of gap junctions. Biophys J, 52, 441–454.
   PubMed Web of Science ®Google Scholar
• Agren UM, Tammi RH, Tammi MI. (1997). Reactive oxygen species contribute to epidermal hyaluronan catabolism in human skin organ culture. Free Radic Biol Med, 23, 996–1001.
   PubMed Web of Science ®Google Scholar
• Akima K, Ito H, Iwata Y, Matsuo K, Watari N, Yanagi M, Hagi H, Oshima K, Yagita A, Atomi Y, Tatekawa I. (1996). Evaluation of antitumor activities of hyaluronate binding antitumor drugs: synthesis, characterization and antitumor activity. J Drug Target, 4, 1–8.
   PubMed Web of Science ®Google Scholar
• Al-Ghananeem AM, Malkawi AH, Muammer YM, Balko JM, Black EP, Mourad W, Romond E. (2009). Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations. AAPS PharmSciTech, 10, 410–417.
   PubMed Web of Science ®Google Scholar
• Arch R, Wirth K, Hofmann M, Ponta H, Matzku S, Herrlich P, Zöller M. (1992). Participation in normal immune responses of a metastasis inducing splice variant of CD44. Science, 257, 682–685.
   PubMed Web of Science ®Google Scholar
• Auzenne E, Ghosh SC, Khodadadian M, Rivera B, Farquhar D, Price RE, Ravoori M, Kundra V, Freedman RS, Klostergaard J. (2007). Hyaluronic acid-paclitaxel: antitumor efficacy against CD44(+) human ovarian carcinoma xenografts. Neoplasia, 9, 479–486.
   PubMed Web of Science ®Google Scholar
• Bacso Z, Nagy H, Goda K, Bene L, Fenyvesi F, Matkó J, Szabó G. (2004). Raft and cytoskeleton associations of an ABC transporter: P-glycoprotein. Cytometry A, 61, 105–116.
   PubMed Web of Science ®Google Scholar
• Bajorath J, Greenfield B, Munro SB, Day AJ, Aruffo A. (1998). Identification of CD44 residues important for hyaluronan binding and delineation of the binding site. J Biol Chem, 273, 338–343.
   PubMed Web of Science ®Google Scholar
• Bansal T, Akhtar N, Jaggi M, Khar RK, Talegaonkar S. (2009). Novel formulation approaches for optimising delivery of anticancer drugs based on P-glycoprotein modulation. Drug Discov Today, 14, 1067–1074.
   PubMed Web of Science ®Google Scholar
• Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Meléndez-Alafort L, Mazzi U, Zanovello P, Rosato A. (2008). A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent in vivo therapeutic activity. Clin Cancer Res, 14, 3598–3606.
   PubMed Web of Science ®Google Scholar
• Baumgartner G, Gomar-Höss C, Sakr L, Ulsperger E, Wogritsch C. (1998). The impact of extracellular matrix on the chemoresistance of solid tumors–experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy. Cancer Lett, 131, 85–99.
   PubMed Web of Science ®Google Scholar
• Baumgartner G. (1987). [Hyaluronidase in the therapy of malignant diseases]. Wien Klin Wochenschr Suppl, 174, 1–22.
   PubMedGoogle Scholar
• Bhang SH, Won N, Lee TJ, Jin H, Nam J, Park J, Chung H, Park HS, Sung YE, Hahn SK, Kim BS, Kim S. (2009). Hyaluronic acid-quantum dot conjugates for in vivo lymphatic vessel imaging. ACS Nano, 3, 1389–1398.
   PubMed Web of Science ®Google Scholar
• Bishop JR, Schuksz M, Esko JD. (2007). Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature, 446, 1030–1037.
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Spevak CC, Wong G, Xia W, Gilad E. (2009). Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem, 284, 26533–26546.
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Zhu H, Chu A, Iida N, Zhang L, Hung MC. (1997). Interaction between the adhesion receptor, CD44, and the oncogene product, p185HER2, promotes human ovarian tumor cell activation. J Biol Chem, 272, 27913–27918.
   PubMed Web of Science ®Google Scholar
• Bourguignon LY, Peyrollier K, Xia W, Gilad E. (2008). Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J Biol Chem, 283, 17635–17651.
   PubMed Web of Science ®Google Scholar
• Brecht M, Mayer U, Schlosser E, Prehm P. (1986). Increased hyaluronate synthesis is required for fibroblast detachment and mitosis. Biochem J, 239, 445–450.
   PubMed Web of Science ®Google Scholar
• Cho HJ, Yoon HY, Koo H, Ko SH, Shim JS, Lee JH, Kim K, Kwon IC, Kim DD. (2011). Self-assembled nanoparticles based on hyaluronic acid-ceramide (HA-CE) and Pluronic® for tumor-targeted delivery of docetaxel. Biomaterials, 32, 7181–7190.
   PubMed Web of Science ®Google Scholar
• Coradini D, Zorzet S, Rossin R, Scarlata I, Pellizzaro C, Turrin C, Bello M, Cantoni S, Speranza A, Sava G, Mazzi U, Perbellini A. (2004). Inhibition of hepatocellular carcinomas in vitro and hepatic metastases in vivo in mice by the histone deacetylase inhibitor HA-But. Clin Cancer Res, 10, 4822–4830.
   PubMed Web of Science ®Google Scholar
• Dean M, Allikmets R. (2001). Complete characterization of the human ABC gene family. J Bioenerg Biomembr, 33, 475–479.
   PubMed Web of Science ®Google Scholar
• DeGrendele HC, Kosfiszer M, Estess P, Siegelman MH. (1997). CD44 activation and associated primary adhesion is inducible via T cell receptor stimulation. J Immunol, 159, 2549–2553.
   PubMed Web of Science ®Google Scholar
• Eliaz RE, Szoka FC Jr. (2001). Liposome-encapsulated doxorubicin targeted to CD44: a strategy to kill CD44-overexpressing tumor cells. Cancer Res, 61, 2592–2601.
   PubMed Web of Science ®Google Scholar
• Estess P, DeGrendele HC, Pascual V, Siegelman MH. (1998). Functional activation of lymphocyte CD44 in peripheral blood is a marker of autoimmune disease activity. J Clin Invest, 102, 1173–1182.
   PubMed Web of Science ®Google Scholar
• Faassen AE, Schrager JA, Klein DJ, Oegema TR, Couchman JR, McCarthy JB. (1992). A cell surface chondroitin sulfate proteoglycan, immunologically related to CD44, is involved in type I collagen-mediated melanoma cell motility and invasion. J Cell Biol, 116, 521–531.
   PubMed Web of Science ®Google Scholar
• Fjeldstad K, Kolset SO. (2005). Decreasing the metastatic potential in cancers–targeting the heparan sulfate proteoglycans. Curr Drug Targets, 6, 665–682.
   PubMed Web of Science ®Google Scholar
• Goodfellow PN, Banting G, Wiles MV, Tunnacliffe A, Parkar M, Solomon E, Dalchau R, Fabre JW. (1982). The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol, 12, 659–663.
   PubMed Web of Science ®Google Scholar
• Goodison S, Tarin D. (1998). Clinical implications of anomalous CD44 gene expression in neoplasia. Front Biosci, 3, e89–109.
   PubMedGoogle Scholar
• Green SJ, Tarone G, Underhill CB. (1988). Aggregation of macrophages and fibroblasts is inhibited by a monoclonal antibody to the hyaluronate receptor. Exp Cell Res, 178, 224–232.
   PubMed Web of Science ®Google Scholar
• Hajime M, Shuichi Y, Makoto N, Masanori Y, Ikuko K, Atsushi K, Mutsuo S, Keiichi T. (2007). Inhibitory effect of 4-methylesculetin on hyaluronan synthesis slows the development of human pancreatic cancer in vitro and in nude mice. Int J Cancer, 120, 2704–2709.
   PubMed Web of Science ®Google Scholar
• Hamilton SR, Fard SF, Paiwand FF, Tolg C, Veiseh M, Wang C, McCarthy JB, Bissell MJ, Koropatnick J, Turley EA. (2007). The hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cells. J Biol Chem, 282, 16667–16680.
   PubMed Web of Science ®Google Scholar
• He M, Zhao Z, Yin L, Tang C, Yin C. (2009). Hyaluronic acid coated poly(butyl cyanoacrylate) nanoparticles as anticancer drug carriers. Int J Pharm, 373, 165–173.
   PubMed Web of Science ®Google Scholar
• Hyung W, Ko H, Park J, Lim E, Park SB, Park YJ, Yoon HG, Suh JS, Haam S, Huh YM. (2008). Novel hyaluronic acid (HA) coated drug carriers (HCDCs) for human breast cancer treatment. Biotechnol Bioeng, 99, 442–454.
   PubMed Web of Science ®Google Scholar
• Itano N, Zhuo L, Kimata K. (2008). Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci, 99, 1720–1725.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK, Ganesh N, Barve J, Beg AM. (2010). Design and development of ligand-appended polysaccharidic nanoparticles for the delivery of oxaliplatin in colorectal cancer. Nanomedicine, 6, 179–190.
   PubMed Web of Science ®Google Scholar
• Jain A, Jain SK. (2008). In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. Eur J Pharm Sci, 35, 404–416.
   PubMed Web of Science ®Google Scholar
• Jalkanen S, Jalkanen M. (1992). Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin. J Cell Biol, 116, 817–825.
   PubMed Web of Science ®Google Scholar
• Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE. (2006). Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med, 12, 1167–1174.
   PubMed Web of Science ®Google Scholar
• Journo-Gershfeld G, Kapp D, Shamay Y, Kopecek J, David A. (2012). Hyaluronan oligomers-HPMA copolymer conjugates for targeting paclitaxel to CD44-overexpressing ovarian carcinoma. Pharm Res, 29, 1121–1133.
   PubMed Web of Science ®Google Scholar
• Karihtala P, Soini Y, Auvinen P, Tammi R, Tammi M, Kosma VM. (2007). Hyaluronan in breast cancer: correlations with nitric oxide synthases and tyrosine nitrosylation. J Histochem Cytochem, 55, 1191–1198.
   PubMed Web of Science ®Google Scholar
• Katoh S, McCarthy JB, Kincade PW. (1994). Characterization of soluble CD44 in the circulation of mice. Levels are affected by immune activity and tumor growth. J Immunol, 153, 3440–3449.
   PubMed Web of Science ®Google Scholar
• Kim EJ, Shim G, Kim K, Kwon IC, Oh YK, Shim CK. (2009). Hyaluronic acid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J Gene Med, 11, 791–803.
   PubMed Web of Science ®Google Scholar
• Kim J, Kim KS, Jiang G, Kang H, Kim S, Kim BS, Park MH, Hahn SK. (2008). In vivo real-time bioimaging of hyaluronic acid derivatives using quantum dots. Biopolymers, 89, 1144–1153.
   PubMed Web of Science ®Google Scholar
• Knudson W. (1996). Tumor-associated hyaluronan. Providing an extracellular matrix that facilitates invasion. Am J Pathol, 148, 1721–1726.
   PubMed Web of Science ®Google Scholar
• Knutson JR, Iida J, Fields GB, McCarthy JB. (1996). CD44/chondroitin sulfate proteoglycan and α 2 β 1 integrin mediate human melanoma cell migration on type IV collagen and invasion of basement membranes. Mol Biol Cell, 7, 383–396.
   PubMed Web of Science ®Google Scholar
• Koyama H, Hibi T, Isogai Z, Yoneda M, Fujimori M, Amano J, Kawakubo M, Kannagi R, Kimata K, Taniguchi S, Itano N. (2007). Hyperproduction of hyaluronan in neu-induced mammary tumor accelerates angiogenesis through stromal cell recruitment: possible involvement of versican/PG-M. Am J Pathol, 170, 1086–1099.
   PubMed Web of Science ®Google Scholar
• Lee H, Ahn CH, Park TG. (2009). Poly[lactic-co-(glycolic acid)]-grafted hyaluronic acid copolymer micelle nanoparticles for target-specific delivery of doxorubicin. Macromol Biosci, 9, 336–342.
   PubMed Web of Science ®Google Scholar
• Lee Y, Lee H, Kim YB, Kim J, Hyeon T, Park H, Messersmith PB, Park TG. (2008). Bioinspired Surface Immobilization of Hyaluronic Acid on Monodisperse Magnetite Nanocrystals for Targeted Cancer Imaging. Adv Mater Weinheim, 20, 4154–4157.
   PubMed Web of Science ®Google Scholar
• Lees VC, Fan TP, West DC. (1995). Angiogenesis in a delayed revascularization model is accelerated by angiogenic oligosaccharides of hyaluronan. Lab Invest, 73, 259–266.
   PubMed Web of Science ®Google Scholar
• Li SD, Howell SB. (2010). CD44-targeted microparticles for delivery of cisplatin to peritoneal metastases. Mol Pharm, 7, 280–290.
   PubMedGoogle Scholar
• Lin EY, Li JF, Gnatovskiy L, Deng Y, Zhu L, Grzesik DA, Qian H, Xue XN, Pollard JW. (2006). Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res, 66, 11238–11246.
   PubMed Web of Science ®Google Scholar
• Luo Y, Prestwich GD. (1999). Synthesis and selective cytotoxicity of a hyaluronic acid-antitumor bioconjugate. Bioconjug Chem, 10, 755–763.
   PubMed Web of Science ®Google Scholar
• Matsumura Y, Hanbury D, Smith J, Tarin D. (1994). Non-invasive detection of malignancy by identification of unusual CD44 gene activity in exfoliated cancer cells. BMJ, 308, 619–624.
   PubMed Web of Science ®Google Scholar
• McKee CM, Penno MB, Cowman M, Burdick MD, Strieter RM, Bao C, Noble PW. (1996). Hyaluronan (HA) fragments induce chemokine gene expression in alveolar macrophages. The role of HA size and CD44. J Clin Invest, 98, 2403–2413.
   PubMed Web of Science ®Google Scholar
• Meo CD, Panza L, Capitani D, Mannina L, Banzato A, Rondina M, Renier D, Rosato A, Crescenzi V. (2007). Hyaluronan as carrier of carboranes for tumor targeting in boron neutron capture therapy. Biomacromolecules, 8, 552–559.
   PubMed Web of Science ®Google Scholar
• Miletti-González KE, Chen S, Muthukumaran N, Saglimbeni GN, Wu X, Yang J, Apolito K, Shih WJ, Hait WN, Rodríguez-Rodríguez L. (2005). The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer. Cancer Res, 65, 6660–6667.
   PubMed Web of Science ®Google Scholar
• Mohamadzadeh M, DeGrendele H, Arizpe H, Estess P, Siegelman M. (1998). Proinflammatory stimuli regulate endothelial hyaluronan expression and CD44/HA-dependent primary adhesion. J Clin Invest, 101, 97–108.
   PubMed Web of Science ®Google Scholar
• Monz K, Maas-Kück K, Schumacher U, Schulz T, Hallmann R, Schnäker EM, Schneider SW, Prehm P. (2008). Inhibition of hyaluronan export attenuates cell migration and metastasis of human melanoma. J Cell Biochem, 105, 1260–1266.
   PubMed Web of Science ®Google Scholar
• Nair HB, Huffman S, Veerapaneni P, Kirma NB, Binkley P, Perla RP, Evans DB, Tekmal RR. (2011). Hyaluronic acid-bound letrozole nanoparticles restore sensitivity to letrozole-resistant xenograft tumors in mice. J Nanosci Nanotechnol, 11, 3789–3799.
   PubMed Web of Science ®Google Scholar
• Naor D, Sionov RV, Ish-Shalom D. (1997). CD44: structure, function, and association with the malignant process. Adv Cancer Res, 71, 241–319.
   PubMed Web of Science ®Google Scholar
• Park W, Kim KS, Bae BC, Kim YH, Na K. (2010). Cancer cell specific targeting of nanogels from acetylated hyaluronic acid with low molecular weight. Eur J Pharm Sci, 40, 367–375.
   PubMed Web of Science ®Google Scholar
• Peck D, Isacke CM. (1996). CD44 phosphorylation regulates melanoma cell and fibroblast migration on, but not attachment to, a hyaluronan substratum. Curr Biol, 6, 884–890.
   PubMed Web of Science ®Google Scholar
• Peer D, Margalit R. (2004a). Loading mitomycin C inside long circulating hyaluronan targeted nano-liposomes increases its antitumor activity in three mice tumor models. Int J Cancer, 108, 780–789.
   PubMed Web of Science ®Google Scholar
• Peer D, Margalit R. (2004b). Tumor-targeted hyaluronan nanoliposomes increase the antitumor activity of liposomal Doxorubicin in syngeneic and human xenograft mouse tumor models. Neoplasia, 6, 343–353.
   PubMed Web of Science ®Google Scholar
• Pessac B, Defendi V. (1972). Cell aggregation: role of acid mucopolysaccharides. Science, 175, 898–900.
   PubMed Web of Science ®Google Scholar
• Qhattal HS, Liu X. (2011). Characterization of CD44-mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm, 8, 1233–1246.
   PubMed Web of Science ®Google Scholar
• Raguz S, Tamburo De Bella M, Tripuraneni G, Slade MJ, Higgins CF, Coombes RC, Yagüe E. (2004). Activation of the MDR1 upstream promoter in breast carcinoma as a surrogate for metastatic invasion. Clin Cancer Res, 10, 2776–2783.
   PubMed Web of Science ®Google Scholar
• Ricciardelli C, Russell DL, Ween MP, Mayne K, Suwiwat S, Byers S, Marshall VR, Tilley WD, Horsfall DJ. (2007). Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J Biol Chem, 282, 10814–10825.
   PubMed Web of Science ®Google Scholar
• Saravanakumar G, Choi KY, Yoon HY, Kim K, Park JH, Kwon IC, Park K. (2010). Hydrotropic hyaluronic acid conjugates: Synthesis, characterization, and implications as a carrier of paclitaxel. Int J Pharm, 394, 154–161.
   PubMed Web of Science ®Google Scholar
• Sauter A, Kloft C, Gronau S, Bogeschdorfer F, Erhardt T, Golze W, Schroen C, Staab A, Riechelmann H, Hoermann K. (2007). Pharmacokinetics, immunogenicity and safety of bivatuzumab mertansine, a novel CD44v6-targeting immunoconjugate, in patients with squamous cell carcinoma of the head and neck. Int J Oncol, 30, 927–935.
   PubMed Web of Science ®Google Scholar
• Schoppmann SF, Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Kriehuber E, Nagy K, Alitalo K, Kerjaschki D. (2002). Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol, 161, 947–956.
   PubMed Web of Science ®Google Scholar
• Shuster S, Frost GI, Csoka AB, Formby B, Stern R. (2002). Hyaluronidase reduces human breast cancer xenografts in SCID mice. Int J Cancer, 102, 192–197.
   PubMed Web of Science ®Google Scholar
• Shi X, Wang S, Meshinchi S, Van Antwerp ME, Bi X, Lee I, Baker JR Jr. (2007). Dendrimer-entrapped gold nanoparticles as a platform for cancer-cell targeting and imaging. Small, 3, 1245–1252.
   PubMed Web of Science ®Google Scholar
• Sironen RK, Tammi M, Tammi R, Auvinen PK, Anttila M, Kosma VM. (2011). Hyaluronan in human malignancies. Exp Cell Res, 317, 383–391.
   PubMed Web of Science ®Google Scholar
• Sneath RJ, Mangham DC. (1998). The normal structure and function of CD44 and its role in neoplasia. MP, Mol Pathol, 51, 191–200.
   PubMedGoogle Scholar
• Somasunderam A, Thiviyanathan V, Tanaka T, Li X, Neerathilingam M, Lokesh GL, Mann A, Peng Y, Ferrari M, Klostergaard J, Gorenstein DG. (2010). Combinatorial selection of DNA thioaptamers targeted to the HA binding domain of human CD44. Biochemistry, 49, 9106–9112.
   PubMed Web of Science ®Google Scholar
• Stern R. (2005). Hyaluronan metabolism: a major paradox in cancer biology. Pathol Biol, 53, 372–382.
   PubMed Web of Science ®Google Scholar
• Sugiyama M, Woodman A, Sugino T, Crowley S, Ho K, Smith J, Matsumura Y, Tarin D. (1995). Non-invasive detection of bladder cancer by identification of abnormal CD44 proteins in exfoliated cancer cells in urine. Clin Mol Pathol, 48, M142–M147.
   PubMedGoogle Scholar
• Sugiyama Y, Shimada A, Sayo T, Sakai S, Inoue S. (1998). Putative hyaluronan synthase mRNA are expressed in mouse skin and TGF-β upregulates their expression in cultured human skin cells. J Invest Dermatol, 110, 116–121.
   PubMed Web of Science ®Google Scholar
• Tammi R, Rilla K, Pienimaki JP, MacCallum DK, Hogg M, Luukkonen M, Hascall VC, Tammi M. (2001). Hyaluronan enters keratinocytes by a novel endocytic route for catabolism. J Biol Chem, 276, 35111–35122.
   PubMed Web of Science ®Google Scholar
• Tammi RH, Kultti A, Kosma VM, Pirinen R, Auvinen P, Tammi MI. (2008). Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Semin Cancer Biol, 18, 288–295.
   PubMed Web of Science ®Google Scholar
• Tijink BM, Buter J, de Bree R, Giaccone G, Lang MS, Staab A, Leemans CR, van Dongen GA. (2006). A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus. Clin Cancer Res, 12, 6064–6072.
   PubMed Web of Science ®Google Scholar
• Toole BP. (1997). Hyaluronan in morphogenesis. J Intern Med, 242, 35–40.
   PubMed Web of Science ®Google Scholar
• Toyama-Sorimachi N, Miyasaka M. (1994). A novel ligand for CD44 is sulfated proteoglycan. Int Immunol, 6, 655–660.
   PubMed Web of Science ®Google Scholar
• Trochon V, Mabilat C, Bertrand P, Legrand Y, Smadja-Joffe F, Soria C, Delpech B, Lu H. (1996). Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer, 66, 664–668.
   PubMed Web of Science ®Google Scholar
• Trowbridge IS, Lesley J, Schulte R, Hyman R, Trotter J. (1982). Biochemical characterization and cellular distribution of a polymorphic, murine cell-surface glycoprotein expressed on lymphoid tissues. Immunogenetics, 15, 299–312.
   PubMed Web of Science ®Google Scholar
• Tsatas D, Kanagasundaram V, Kaye A, Novak U. (2002). EGF receptor modifies cellular responses to hyaluronan in glioblastoma cell lines. J Clin Neurosci, 9, 282–288.
   PubMed Web of Science ®Google Scholar
• Udabage L, Brownlee GR, Waltham M, Blick T, Walker EC, Heldin P, Nilsson SK, Thompson EW, Brown TJ. (2005). Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer. Cancer Res, 65, 6139–6150.
   PubMed Web of Science ®Google Scholar
• Underhill C, Dorfman A. (1978). The role of hyaluronic acid in intercellular adhesion of cultured mouse cells. Exp Cell Res, 117, 155–164.
   PubMed Web of Science ®Google Scholar
• Underhill CB, Toole BP. (1981). Receptors for hyaluronate on the surface of parent and virus-transformed cell lines: binding and aggregation studies. Exp Cell Res, 131, 419–423.
   PubMed Web of Science ®Google Scholar
• Underhil C. 1992. Cd44; the hyaluronan receptor. J Cell Sci,103, 293–298.
   PubMed Web of Science ®Google Scholar
• Weber GF, Ashkar S, Cantor H. (1997). Interaction between CD44 and osteopontin as a potential basis for metastasis formation. Proc Assoc Am Physicians, 109, 1–9.
   PubMedGoogle Scholar
• West DC, Kumar S. (1989). The effect of hyaluronate and its oligosaccharides on endothelial cell proliferation and monolayer integrity. Exp Cell Res, 183, 179–196.
   PubMed Web of Science ®Google Scholar
• Yadav AK, Mishra P, Mishra AK, Mishra P, Jain S, Agrawal GP. (2007). Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin. Nanomedicine, 3, 246–257.
   PubMed Web of Science ®Google Scholar
• Yokoo M, Miyahayashi Y, Naganuma T, Kimura N, Sasada H, Sato E. (2002). Identification of hyaluronic acid-binding proteins and their expressions in porcine cumulus-oocyte complexes during in vitro maturation. Biol Reprod, 67, 1165–1171.
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. (1999). Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev, 13, 35–48.
   PubMed Web of Science ®Google Scholar
• Yu Q, Stamenkovic I. (2000). Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-β and promotes tumor invasion and angiogenesis. Genes Dev, 14, 163–176.
   PubMed Web of Science ®Google Scholar
• Yu WH, Woessner JF Jr, McNeish JD, Stamenkovic I. (2002). CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev, 16, 307–323.
   PubMed Web of Science ®Google Scholar
• Yun YH, Goetz DJ, Yellen P, Chen W. (2004). Hyaluronan microspheres for sustained gene delivery and site-specific targeting. Biomaterials, 25, 147–157.
   PubMed Web of Science ®Google Scholar
• Zhang LS, Greyner HJ, Mummert ME, Petroll WM. (2009). Development of a hyaluronan bioconjugate for the topical treatment of melanoma. J Dermatol Sci, 55, 56–59.
   PubMed Web of Science ®Google Scholar